Molecular staging of prostate cancer in the year 2007

被引:18
作者
Schlomm, Thorsten
Erbersdobler, Andreas
Mirlacher, Martina
Sauter, Guido
机构
[1] Univ Hamburg, Med Ctr, Prostate Canc Ctr, Martini Clin, D-20246 Hamburg, Germany
[2] Univ Hamburg, Med Ctr, Dept Pathol, D-20246 Hamburg, Germany
关键词
prostate cancer; genes; prognosis; prediction; targeted therapy; molecular staging; microarray;
D O I
10.1007/s00345-007-0153-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Numerous attempts towards improving patient management by molecular staging have been fruitless so far. No single molecular parameter is routinely analyzed in prostate cancer tissue. This may be partly due to genuine properties of prostate cancer that may make this tumor a difficult target. Furthermore, inherent logistical problems result in a shortage of prostate cancer tissue for research purposes. For the future, it can be hoped that the availability of more powerful molecular techniques in combination with better tissue archives will allow more rapid progress. Powerful DNA array and proteomics methods allow the systematic analysis of virtually all genes of a cancer on the DNA, RNA, and protein level. Although such approaches are sometimes labeled as "fishing expeditions," it cannot be totally disregarded that the simultaneous analysis of all genes has a high likelihood of identifying significant new information. In future, one of the major scientific challenges will be the validation of several potential biomarkers in large enough and clinically well-characterized patient cohorts. In particular, studies on needle core biopsies and hormone refractory cancers are imperatively needed for investigating the natural history of the disease or to discover potential predictive markers for radiation therapy and new therapeutic target genes to answer the clinically most important questions for optimal clinical decision making in prostate cancer patients: which patients will not require local therapy? If local therapy is needed, what is the treatment of choice? What medications should be given if metastases are present?
引用
收藏
页码:19 / 30
页数:12
相关论文
共 99 条
[1]   α-Catenin expression has prognostic value in local and locally advanced prostate cancer [J].
Aaltomaa, S ;
Lipponen, P ;
Ala-Opas, M ;
Eskelinen, M ;
Kosma, VM .
BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) :477-482
[2]   Apoptosis in prostate cancer: Bax correlation with stage [J].
Amirghofran, Z ;
Monabati, A ;
Gholijani, N .
INTERNATIONAL JOURNAL OF UROLOGY, 2005, 12 (04) :340-345
[3]   Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy [J].
Andre, Fabrice ;
Pusztai, Lajos .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (11) :621-632
[4]   bcl-2 Overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer [J].
Apakama, I ;
Robinson, MC ;
Walter, NM ;
Charlton, RG ;
Royds, JA ;
Fuller, CE ;
Neal, DE ;
Hamdy, FC .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1258-1262
[5]   Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy [J].
Augustin, H ;
Hammerer, PG ;
Graefen, M ;
Palisaar, J ;
Daghofer, F ;
Huland, H ;
Erbersdobler, A .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (11) :662-668
[6]  
Bakin RE, 2003, CANCER RES, V63, P1981
[7]   Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy:: prognostic significance of p21/WAF1/CIP1 expression [J].
Baretton, GB ;
Klenk, U ;
Diebold, J ;
Schmeller, N ;
Löhrs, U .
BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) :546-555
[8]  
Bauer JJ, 1995, CLIN CANCER RES, V1, P1295
[9]  
Bonkhoff H, 2005, PATHOLOGE, V26, P453, DOI 10.1007/s00292-005-0791-0
[10]   Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status [J].
Bonkhoff, H .
ANNALS OF ONCOLOGY, 2001, 12 :S141-S144